They found that HER2-positive breast cancer cells express neuromedin U(NmU), which blocks the immune response and promotes the expression of immunosuppressive molecules, such as TGFβ1., therefore functionally affecting ADCC and inducing trastuzumab resistance. Here, ERBB2 is linked to breast cancer.